Zhibing Zheng

Prof. Zhibing Zheng


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 September 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
PLPengyun Li
Pengyun Li
QLQiaohong Lin
Qiaohong Lin
SSShiyang Sun
Shiyang Sun
NYNing Yang
Ning Yang
YXYu Xia
Yu Xia
SLSong Li
Song Li
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that displays highly aggressive with poor prognosis. Owing to the limited targets and drugs for TNBC clinical therapy, it is necessary to investigate the factors regulating cancer progression and develop novel therapies for cancer treatment. Ferroptosis, a nonapoptotic form of programmed cell death characterized by accumulation of iron-dependent peroxidation of phospholipids, is regulated by cellular metabolism, redox homeostasis, and various cancer-related signaling pathways. Recently, considerable progress has been made in demonstrating the critical role of lipid metabolism in regulating ferroptosis, indicating potential combinational therapeutic strategies for cancer treatment. In this study, by drug combination screen of lipid metabolism compounds with ferroptosis inducers in decreasing TNBC cell viability, we found potent synergy of the CB1 antagonist rimonabant with erastin/(1 S, 3 R)-RSL3 (RSL3) in inhibiting TNBC cell growth both in vitro and in vivo via promoting the levels of lipid peroxides, malondialdehyde (MDA), 4-hydroxynonenal (4-HNE) and cytosolic reactive oxygen species (ROS) production, enhancing intracellular glutathione (GSH) depletion and inducing G1 cell cycle arrest. We identified that inhibition of CB1 promoted the effect of erastin/RSL3 on inducing ferroptosis and enhanced their inhibitory effect on tumor growth. Using RNA-Seq, fatty acid analyses and functional assays, we found that CB1 regulated stearoyl-CoA desaturase 1 (SCD1)- and fatty acyl desaturase 2 (FADS2)-dependent fatty acid metabolism via phosphatidylinositol 3 kinase (PI3K)-AKT and mitogen-activated protein kinase (MAPK) signaling pathways to modulate ferroptosis sensitivity in TNBC cells. These data demonstrate that dual targeting of CB1 and ferroptosis could be a promising therapeutic strategy for TNBC.

13 October 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
NYNing Yang
Ning Yang
ZFZhiya Fan
Zhiya Fan
SSShiyang Sun
Shiyang Sun
XHXiaotong Hu
Xiaotong Hu
YMYaqiu Mao
Yaqiu Mao
SLSong Li
Song Li

6 June 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
WZWenjuan Zhang
Wenjuan Zhang
PLPengyun Li
Pengyun Li
SSShiyang Sun
Shiyang Sun
CJChangkai Jia
Changkai Jia
NYNing Yang
Ning Yang
SLSong Li
Song Li

19 January 2023 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
PLPengyun Li
Pengyun Li
CJChangkai Jia
Changkai Jia
ZFZhiya Fan
Zhiya Fan
XHXiaotong Hu
Xiaotong Hu
WZWenjuan Zhang
Wenjuan Zhang
SLSong Li
Song Li
Various c-mesenchymal-to-epithelial transition (c-MET) inhibitors are effective in the treatment of non-small cell lung cancer; however, the inevitable drug resistance remains a challenge, limiting their clinical efficacy. Therefore, novel strategies targeting c-MET are urgently required. Herein, through rational structure optimization, we obtained novel exceptionally potent and orally active c-MET proteolysis targeting chimeras (PROTACs) namely D10 and D15 based on thalidomide and tepotinib. D10 and D15 inhibited cell growth with low nanomolar IC50 values and achieved picomolar DC50 values and >99% of maximum degradation (Dmax) in EBC-1 and Hs746T cells. Mechanistically, D10 and D15 dramatically induced cell apoptosis, G1 cell cycle arrest and inhibited cell migration and invasion. Notably, intraperitoneal administration of D10 and D15 significantly inhibited tumor growth in the EBC-1 xenograft model and oral administration of D15 induced approximately complete tumor suppression in the Hs746T xenograft model with well-tolerated dose-schedules. Furthermore, D10 and D15 exerted significant anti-tumor effect in cells with c-METY1230H and c-METD1228N mutations, which are resistant to tepotinib in clinic. These findings demonstrated that D10 and D15 could serve as candidates for the treatment of tumors with MET alterations.

1 January 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TYTingting Yang
Tingting Yang
WZWenjuan Zhang
Wenjuan Zhang
SCShengjie Cao
Shengjie Cao
SSShiyang Sun
Shiyang Sun
XCXu Cai
Xu Cai
SLSong Li
Song Li

1 August 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
ZWZhao Wei
Zhao Wei
YLYan-Qin Liu
Yan-Qin Liu
SWSheng-Zheng Wang
Sheng-Zheng Wang
LYLin Yao
Lin Yao
HNHui-Fang Nie
Hui-Fang Nie
SLSong Li
Song Li